AstraZeneca-Oxford developer blasts Canada's approach to vaccine, says 'messing around is going to cost lives'
Oxford University regius professor of medicine Sir John Bell told CTV News’ Question Period, Canada’s approach to AstraZeneca use specifically is reflective of the country’s overall vaccine strategy: “acting on a lot of hearsay not facts.”
“What we can see is that the more people with a second dose, the more people will have antibody levels that are high enough to deal with the Indian variant, which is where we are at the moment, in the U.K. So my advice is get people two doses, as fast as you can and hunker down,” he said.
And on the mixing of vaccines, Bell, who has intimate knowledge of the study currently taking place at the University of Oxford, said initial findings show severe side effect outcomes.
“Our experience to date is that it produces pretty severe reactogenicity, so severe that we don't think that's going to be viable and by that I mean, you get your second dose if you flip it over, you'll get really sick, so I would not advise that,” he said.
Modelling suggests countries struggling to immunise populations could adopt UK strategy
They found that getting a single dose to more people by delaying the second shot would save lives. In people under 65, where the vaccine efficacy is 80% and only 0.1% to 0.3% of the population a day is vaccinated, between 47 and 26 deaths per 100,000 people could be averted, they say in their paper in the British Medical Journal.
If you can show me some data that shows delaying the second dose is costing lives, I'd love to see it.